Biogen (BIIB) Q3 2026 Earnings Call Transcript
Biogen (BIIB) Q3 2026 Earnings Call Transcript（摘要待生成）
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened - Yahoo Finance
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened - Yahoo Finance（摘要待生成）
Biogen earnings beat by $0.60, revenue topped estimates
Biogen earnings beat by $0.60, revenue topped estimates（摘要待生成）
Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack.
Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack.（摘要待生成）
UBS raises Biogen target to $270 from $240, maintains Buy
On Oct. 9, UBS analyst Michael Yee raised the price target to $270 from $240 and maintained Buy. BIIB closed at $225.71, up 3.33% that day; the source does not attribute the move to the analyst action.
RBC cuts Biogen target to $256 from $260, maintains Outperform
On Oct. 8, RBC’s Brian Abrahams cut the target to $256 from $260 and maintained Outperform in a biotech Q3 preview. RBC cited additional selling days and mid-year price increases as support for large-cap results. BIIB closed down 1.67% at $218.43 on Oct. 8.